ESR1 and breast cancer: The results showed TICRR displayed the highest expression in triple-negative breast cancer (TNBC, ER/PR-negative, and HER2-negative), followed by HER2-positive breast cancer (HER2, ER/PR-negative, and HER2-positive) (Figure 9B), which are both associated with shorter survival time (32).